This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Deneka AY , Einarson MB , Bennett J , Nikonova AS , Elmekawy M , Zhou Y , Lee JW , Burtness BA , Golemis EA
Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
Cancers (Basel). 2020 Jan 28;12(2)
PMID: 32012873 PMCID: PMC7072436 URL: https://www.ncbi.nlm.nih.gov/pubmed/32012873
AbstractHead and neck squamous cell carcinomas (HNSCC) affect more than 800,000 people annually worldwide, causing over 15,000 deaths in the US. Among HNSCC cancers, human papillomavirus (HPV)-negative HNSCC has the worst outcome, motivating efforts to improve therapy for this disease. The most common mutational events in HPV-negative HNSCC are inactivation of the tumor suppressors TP53 (>85%) and CDKN2A (>57%), which significantly impairs G1/S checkpoints, causing reliance on other cell cycle checkpoints to repair ongoing replication damage. We evaluated a panel of cell cycle-targeting clinical agents in a group of HNSCC cell lines to identify a subset of drugs with single-agent activity in reducing cell viability. Subsequent analyses demonstrated potent combination activity between the CHK1/2 inhibitor LY2606268 (prexasertib), which eliminates a G2 checkpoint, and the WEE1 inhibitor AZD1775 (adavosertib), which promotes M-phase entry, in induction of DNA damage, mitotic catastrophe, and apoptosis, and reduction of anchorage independent growth and clonogenic capacity. These phenotypes were accompanied by more significantly reduced activation of CHK1 and its paralog CHK2, and enhanced CDK1 activation, eliminating breaks on the mitotic entry of cells with DNA damage. These data suggest the potential value of dual inhibition of CHK1 and WEE1 in tumors with compromised G1/S checkpoints.
NotesDeneka, Alexander Y Einarson, Margret B Bennett, John Nikonova, Anna S Elmekawy, Mohamed Zhou, Yan Lee, Jong Woo Burtness, Barbara A Golemis, Erica A R21 CA181287/NH/NIH HHS/United States R01 DK108195/NH/NIH HHS/United States R50 CA211479/NH/NIH HHS/United States P30 CA006927/NH/NIH HHS/United States Journal Article Switzerland Cancers (Basel). 2020 Jan 28;12(2). pii: cancers12020306. doi: 10.3390/cancers12020306.